Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

Eisai, BioArctic to develop new drug for Alzheimer’s that can cross blood-brain barrier

Eisai and BioArctic — the companies behind the first Alzheimer’s drug proven to slow disease progression — are inking another research partnership in the disease,

April 23, 2024

AAIC 2024: Eisai presents positive long-term data with Leqembi – Pharmaceutical Technology

Leqembi is an anti-amyloid treatment designed to ablate amyloid-beta aggregates, which are a major driver of Alzheimer’s disease. Credits: joshimerbin/Shutterstock.com Eisai has announced that patients

August 1, 2024

Obesity in early pregnancy increases long-term risk of venous thromboembolism

Investigated the association between obesity in early pregnancy and long-term post-pregnancy risk of venous thromboembolism.

September 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.